Medicine Recommendations

Partial-onset seizures with or without secondary generalised seizures

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products   

Schizophrenia and other psychoses, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour

Schizophrenia and other psychoses, mania, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Schizophrenia, monosymptomatic hypochondriacal psychosis, paranoid psychosis

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Hypersalivation Unlicensed

Treatment of narcolepsy with or without cataplexy in adults.

Restless Legs Syndrome (as per LSCMMG Guidelines)

Giant Cell Arteritis

Cluster Headache

Neuropathic pain

Prescribing of Pregabalin for the treatment of Generalised Anxiety Disorder (GAD)

Neuropathic pain (as per LSCMMG Guidelines)

Restless Legs Syndrome (off-licence as per LSCMMG Guidelines)

Nausea and vomiting in the last days of life

Schizophrenia and other psychoses, mania, short term management of severe anxiety

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Drug induced extrapyramidal side effects

The colour classification was determined as part of the collaborative work between LCFT and Medicines Management leads. Local pathways and patient safety were taken into consideration.

Short-term management of psychomotor agitation, agitation and restlessness in the elderly

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Rapid tranquillisation

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration

Insomnia (short term use)

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.